Exclusive: Biotech takes a second stab at cancer drug with troubled history

The drug is believed to be capable of starving cancer cells, based on research out of lauded cancer researcher Bert Vogelstein's lab

March 14, 2025 Check out STAT+

Sponsored By

Last day to get 50% off an annual STAT+ subscription. If you wanted a sign to give yourself a gift this Friday, this is it! Thanks everyone as always. —Alexa Lee, newsletter strategist

Adobe STAT+ | Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein's lab Cage Pharma executives say they see promise in the therapy — 3-bromopyruvate or 3BP — despite a troubled history. By Allison DeAngelis STAT+ | In the Boston area, biotech's hub, a slump is being acutely felt Stocks are down, the industry is grappling with excess lab space, and hiring remains soft, with many biopharma companies continuing to lay off workers. By Robert Weisman — Boston Globe 100 fired CDC employees press RFK Jr. to rehire them, citing shifting guidance In a letter to Robert F. Kennedy Jr., 100 former CDC employees say due process was not followed in firing them and seek to regain their jobs. By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser